Background Psoriatic disease (PsD) is associated with multiple comorbidities. When establishing management protocols, the periodicity for detection and evaluation of such comorbid conditions needs to be specified.
Objectives To establish guidelines for the follow-up of selected comorbidities in patients with PsD.
Methods An expert panel with specialists in Rheumatology, Internal Medicine, Dermatology and General Practitioners defined the comorbidities with higher impact on PsD based on the existing literature and their experience. The periodicity for detection and monitoring of comorbidities in the Rheumatology setting was established by consensus after iterations and systematic review.
Results The expert panel agreed to evaluate comorbidities as part of routine clinical practice at the time of diagnosis, upon changes in systemic treatment and at follow-up visits (evidence level 5, level of agreement 8.8). In any case, monitoring must be customized depending on the risk profile, morbidity, comorbidities and patient preferences. The following table shows the proposed periodicity for detection, assessment, and monitoring of the most important comorbidities in PsD.
Conclusions This proposal for a periodic assessment of comorbidities in patients with PD allows systematic clinical monitoring of the patient by the Rheumatologist and Dermatologist, and can contribute to the early detection and management of these comorbidities
Acknowledgement The GECOAP project was funded by Merck Sharp & Dohme of Spain
Disclosure of Interest None declared